![IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has received an order from CGN Medical Technologies for a Proteus PLUS[1] proton therapy system to be installed in Yangzhou, China](/sites/default/files/styles/content_large/public/ProteusPlus.jpeg?itok=6r5lPqm4)
May 5, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has received an order from CGN Medical Technologies for a Proteus PLUS[1] proton therapy system to be installed in Yangzhou, China. The order marks the first project under the IBA-CGNNT partnership, announced in August 2020. A downpayment has been received for the order and IBA will start to recognize revenue in 2022. The value of this contract for IBA is estimated at around EUR 20 million.
The order includes a Proteus PLUS proton therapy system configured with three-gantry treatment rooms. As part of the agreement, both companies will jointly manufacture, assemble, commission and support all activities of the Proteus®PLUS system in China, as well as delivering a multi-year service contract to be jointly provided to the customer by IBA and CGN.
"Proton therapy, as an advanced and precise treatment modality for patients living with cancer, aligns with the Chinese government's 'Healthy China' strategy and has significant market potential, said Zhu Zeliang, Chairman and General Manager of CGN Medical Technology (Mianyang) Co., Ltd and CGN Isotope (Mianyang) Co., Ltd. "CGN Healthcare will adhere to the mission of Nuclear Technology Makes Human Life Better. That’s why partnering with IBA, a clear market leader in proton therapy technology, truly reinforces our commitment to ensuring cancer patients in China will be provided with more advanced cancer diagnosis, treatment products and services."
“This order demonstrates that our strong partnership with CGNNT is already delivering results,” said Olivier Legrain, CEO of IBA. “By combining IBA’s unrivaled experience in proton therapy with CGN’s leadership position in Nuclear Technology in China, we are ideally placed to expand our strong leadership position in this strategically important territory, with this deal marking our 8th Proteus PLUS proton therapy system to be installed in the region. We are excited to be able to bring a much-needed therapy to patients in China as the proton therapy market continues to expand.”
For more information: www.iba-worldwide.com
July 30, 2024 
